Regions Financial Corp’s Lineage Cell Therapeutics LCTX Stock Holding History

Regions Financial Corp’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-57	Closed	–	–	2136
2018 Q1	$0	Hold	57	–	–	﹤0.01%	2036
2017 Q4	$0	Buy	+57	New	+$124	﹤0.01%	2018

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

IndexIQ Advisors New York $2.82B AUM 12.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Regions Financial Corp's LCTX Position: Q2 2018 in Review

Regions Financial Corp sold out of Lineage Cell Therapeutics (LCTX) in Q2 2018, closing a stake of 57 shares.

Regions Financial Corp first reported a position in LCTX in Q4 2017 and held it in 2 quarters. The position peaked at $0 in Q1 2018. 107 funds tracked by Wall St. Rank hold LCTX as of Q2 2018.

Regions Financial Corp reported no remaining Lineage Cell Therapeutics position as of Q2 2018 after selling out during the quarter.
Regions Financial Corp sold 57 Lineage Cell Therapeutics shares in Q2 2018.
Regions Financial Corp first reported a position in Lineage Cell Therapeutics in Q4 2017 and held it in 2 quarters.
Regions Financial Corp's Lineage Cell Therapeutics position peaked at $0 in Q1 2018.
107 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2018.

Based on Regions Financial Corp's 13F filing for Q2 2018, filed 26 Jul 2018.